Managed Pathology Laboratory Service Contract Birmingham
Managed Pathology Laboratory Service Contract for the provision of clinical chemistry and immunochemistry, immunology, bacterology and infectious serology, coagulopathy, haemoglobinopathy, Point of Care testing, Molecular Biology, and HbA1c testing.
United Kingdom-Birmingham: Pathology services
Section I: Contracting authority
I.1)Name, addresses and contact point(s)
HealthTrust Europe LLP (HTE) acting as agent for Homerton University NHS Foundation Trust
19 George Road, Edgbaston
For the attention of: Danny Haq
B15 1NU Birmingham
Telephone: +44 1216871350
Fax: +44 7870857941
General address of the contracting authority: https://healthtrusteurope.bravosolution.co.uk
Further information can be obtained from: The above mentioned contact point(s)
Specifications and additional documents (including documents for competitive dialogue and a dynamic purchasing system) can be obtained from: The above mentioned contact point(s)
Tenders or requests to participate must be sent to: The above mentioned contact point(s)
I.2)Type of the contracting authority
Other: Please refer to Section II.1.5
I.4)Contract award on behalf of other contracting authorities
Section II: Object of the contract
II.1.1)Title attributed to the contract by the contracting authority:
II.1.2)Type of contract and location of works, place of delivery or of performance
Service category No 25: Health and social services
Main site or location of works, place of delivery or of performance: Homerton University Hospital NHS Foundation Trust, Homerton Row, London E9 6SR.
NUTS code UKI
II.1.3)Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
II.1.5)Short description of the contract or purchase(s)
The Trust provides pathology services to both primary and secondary care. The Trust’s catchment area represents a population of approximately 270 000.
The key aims of this project are to improve efficiency, reduce costs and to deliver an improved diagnostic service to our users. These aims will be achieved by the use of modern analytical equipment combined with a degree of affordable automation. Additionally, there will be a requirement to coordinate equipment implementation with a planned Pathology rebuild project, with occupation date for the combined automated laboratory area expected July 2015 onwards.
It is expected further procurements will be required in future years under this Managed Service Agreement. At this time, there is an intention to include the following:
– Protein Electrophoresis – current workload of 40 000 serum and 1 000 urine myeloma screening tests in addition to 1 000 ALP-isoenzyme and 5 000 Carbohydrate Deficient Transferrin tests p.a. with a value of approximately 130 000 GBP pa. This will be novated into the overarching MLS and re-tendered via the MLS in 2017;
– immunology screening service – consisting of an existing repertoire of anti-tTG, total IgE, anti-CCP and calprotectin testing with value of £80 000 p.a. It is expected that the current portfolio of immunology testing provided will be expanded to include allergy testing and an autoimmune serology screening service over the course of 2015/2016, with current value of approximately 400 000 GBP;
– virology service – the Clinical Biochemistry laboratory currently offers an extensive infectious serology screening service but is seeking to repatriate further workload from the existing out-sourced supplier over the course of 2015/2016, with current value of approximately 400 000 GBP;
– routine haematology service – current workload of 250 000 full blood counts, 20 000 blood films, 32 000 ESR tests and 1 500 malarial parasite screens with value of £150 000 p.a. This will be novated into the overarching MLS and re-tendered via the MLS in 2017;
– blood transfusion service – current workload of 30 000 Group and Screens with value of 110 000 GBP p.a. Planned for tender in 2020 as part of the MLS;
– molecular biology service – current workload of 2 000 HSV screens and 55 000 dual NAATs for assessment of chlamydia and gonorrhoea (though further additions to the testing portfolio are planned) with contract value of approximately £370,000 p.a. This service element is expected to replace the Trust’s current arrangements in April 2016;
– Point of Care Testing (POCT) – the initial scope will involve tender and subsequent novation of the blood gas testing service currently distributed across 9 areas with contract value of approximately 140 000 GBP p.a. to take effect November 2016; though there may follow additional POCT service elements subject to availability of new technologies and dependent on changing service needs.
Additionally the managed service will involve the assumption of the rights and obligations of the Trust pursuant to several existing contracts listed below details of which will be contained in the tender documents.
– protein electrophoresis service by Hydrasys and Capillarys systems currently provided through Sebia with contract end March 2017;
– immunochemistry service by Access2 system, currently provided through Beckman Coulter Diagnostics with a contract end May 2018;
– re-capitalisation and account management of existing Bacteriology suite of analysers, currently provided by Becton Dickenson Diagnostics with combined contact value of 550 000 GBP p.a.;
– blood transfusion service – current workload of 30 000 Group and Screens with value of 110 000 GBP p.a. is to be novated into the MLS until 2020.
The Trust views this as the start of a process to enter into a long-term partnership for the provision and delivery of a service which is fit for purpose, complies with current legislation and, where appropriate, takes account of guidance and best practice in the most efficient, cost effective and timely manner.
The resultant contract arising from this procurement will be entered into between the Trust and the successful bidder.
The duration of the Contract will be 7 years (the ‘Initial Term’) with the option for the Trust to extend the term for a further 7 years (the ‘Secondary Term’), in its sole discretion. In order to establish whether to exercise its right to extend the Contract, the Trust will be entitled to require the contractor (during year 6 and 7 of the Initial Term) to provide all reasonable assistance to the Trust in order for it to carry out a review of the system efficiency, service provision, the market and the Contractor’s performance pursuant to the Contract during the Initial Term. A detailed protocol relating to the above mentioned review will be set out in the Contract Documents. Within the Secondary Term option the contractor must provide options to refresh instrumentation upon commencement of the Secondary Term.
The contract is anticipated to have an initial annual value of approximately 2 000 000 GBP to 2 250 000 GBP and the contact value over a total 14 year term will be approximately between 28 000 000 GBP and 31 500 000 GBP.
The supplier should assume an annual increase in test volumes over the life of the contract. The level of annual growth in this activity is currently running at approximately 5 %. However, in light of the efficiency challenge faced by the NHS as a whole, the Trust would like to work in partnership with the successful bidder to help mitigate the financial impact of this growth.
Please note further information is given about this tender exercise at section VI.3.
II.1.6)Common procurement vocabulary (CPV)
II.1.7)Information about Government Procurement Agreement (GPA)
II.1.9)Information about variants
II.2.1)Total quantity or scope:
II.2.2)Information about options
Description of these options: The duration of the Contract will be 7 years (the ‘Initial Term’) with the option for The Trust to extend the term for a further 7 years (the ‘Secondary Term’), in its sole discretion. In order to establish whether to exercise its right to extend the Contract, the Trust will be entitled to require the contractor (during year 6 and 7 of the Initial Term) to provide all reasonable assistance to the Trust in order for it to carry out a review of the system efficiency, service provision, the market and the Contractor’s performance pursuant to the Contract during the Initial Term. A detailed protocol relating to the above mentioned review will be set out in the Contract Documents. Within the Secondary Term option the contractor must provide options to refresh instrumentation upon commencement of the Secondary Term.
The contract is anticipated to have an initial annual value of approximately 2 250 000 GBP and the contact value over a total 14 year term will be approx. 31 500 000 GBP.
Section III: Legal, economic, financial and technical information
III.1.1)Deposits and guarantees required:
III.1.3)Legal form to be taken by the group of economic operators to whom the contract is to be awarded:
III.2.1)Personal situation of economic operators, including requirements relating to enrolment on professional or trade registers
III.2.2)Economic and financial ability
HTE may request such information as may be requested pursuant to Regulation 25 of the Public Contracts Regulations 2006. Details are provided in the pre-qualification questionnaire.
Section IV: Procedure
IV.1.1)Type of procedure
IV.1.2)Limitations on the number of operators who will be invited to tender or to participate
IV.2.2)Information about electronic auction
IV.3.1)File reference number attributed by the contracting authority:
Homerton University NHS Foundation Trust Ref : HUHFT 2014-03-11
IV.3.4)Time limit for receipt of tenders or requests to participate
IV.3.6)Language(s) in which tenders or requests to participate may be drawn up
Section VI: Complementary information
VI.1)Information about recurrence
VI.2)Information about European Union funds
The full terms and conditions of this contract will be appended to the Invitation to Tender. These terms and conditions include provisions requiring the payment by the supplier of an activity based income management charge in consideration of the award of this contract and the management and administration by HTE of the overall contractual structure and associated documentation, as well as the requirement to submit regular management information to HTE.
Submission of expressions of interest and procurement specific information
This exercise will be conducted on the HTE Bravo portal. Candidates wishing to be considered must register their expression of interest as follows: register on the HTE portal at https://healthtrusteurope.bravosolution.co.uk Login to the portal with the username/password. Click the PQQs/ITTs open to all suppliers link. These are the PQQs/ITTs open to any registered supplier. Click on the relevant PQQ/ ITT to access the content. Click the ‘express interest’ button at the top of the page. This will move the PQQ/ITT into your My PQQs/My ITTS page. You can access any attachments by clicking Buyer Attachments (if required in III.2.1.1.ii) in the PQQ/ITT details box. Follow the on-screen instructions to complete the PQQ/ITT. Submit your reply using the Submit Response button at the top of the page. If you require any further advice, contact the Bravo e-Tendering Help Desk firstname.lastname@example.orgSid4gov
HTE utilises the sid4gov supplier information database. Candidates are requested to register on sid4gov athttps://sid4gov.cabinetoffice.gov.uk/organisation/register and submit their sid4gov company profile for publication on the database. Candidates already registered on sid4gov must ensure that information is up to date. Where access to sid4gov is unavailable, please contact the sid4gov helpdesk email@example.comPlease note that, at present, sid4gov does not pre-populate any fields of the PQQ on HTE’s Bravo portal, and therefore candidates must complete the Qualification and Technical Envelopes of the PQQ in Bravo in full.
VI.4.2)Lodging of appeals
VI.5)Date of dispatch of this notice: